

الجسيم المناعى م البولى كعلامة حيوية جديدة
للكشف عن مدى نشاط الالتهاب الكلى المصاحب لمرض الذئبة
الحمراء

رسالة مقدمه من

الطبيب/ صلاح سعيد محمد

ماجستير الباطنة العامة

عين شمس كلية الطب - جامعة

توطئة للحصول على درجة الدكتوراه فى أمراض الباطنة العامة

تحت إشراف

أ.د/ احمد عزيز عبدالنبي

أستاذ الباطنة العامة و الكلى

عين شمس كلية الطب - جامعة

أ.د/ داليا فايز محمد

أستاذ الباطنة العامة و الروماتيزم

عين شمس كلية الطب - جامعة

أ.د.م/ هيام محمد عارف

أستاذ مساعد الباطنة العامة و الكلى

عين شمس كلية الطب - جامعة

أ.د.م/ رانيا حمدى الكباريتى

أستاذ مساعد الباثولوجيا الاكلينيكية

عين شمس كلية الطب - جامعة

د/ هيثم عزات عبد العزيز

مدرس الباطنة العامة و الكلى

عين شمس كلية الطب - جامعة

كلية الطب

جامعة عين شمس

Urinary immunoglobulin M as a novel biomarker for disease activity of lupus nephritis

Thesis

Submitted For Partial Fulfillment Of Doctorate Degree (M.D)
In Internal Medicine

By

SALAH SAID MOHAMED

M.Sc

*Faculty of medicine
Ain Shams university*

Supervised by

PROF. DR. AHMED AZIZ ABD EL NABI

*Professor Of Internal Medicine &Nephrology
Faculty of medicine
Ain Shams university*

PROF. DR. DALIA FAYEZ MOHAMED

*Professor Of Internal Medicine & Rheumatology
Faculty of medicine
Ain Shams university*

DR. HAYAM MOHAMED AREF

*Ass. Professor Of Internal Medicine &Nephrology
Faculty of medicine
Ain Shams university*

DR. RANIA HAMDY EL-KABARITY

*Ass. Professor Of Clinical pathology
Faculty of medicine
Ain Shams university*

DR. HAITHAM EZZAT ABD-EL AZIZ

*Lecturer Of Internal Medicine &Nephrology
Faculty of medicine
Ain Shams university*

**Faculty of medicine
Ain Shams university**

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ
فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم

النساء: من الآية ١١٣

ACKNOWLEDGEMENT

First of all, I would like to express my prayerful thanks to ALLAH for every thing in my life.

I would like to express my profound gratitude and deep appreciation to PROF. DR.AHMED AZIZ ABD EL NABI, Professor of INTERNAL MEDICINE & NEPHROLOGY, Faculty of Medicine AIN SHAMS University , for giving me the privilege to work under her supervision , her continuous encouragement, guidance and teaching extended beyond scientific scope , to moral and ethical arts of life.

I would like to express my sincere thanks, respect and appreciation to PROF.DR.DALIA FAYEZ MOHAMED, Professor of Rheumatology and Rehabilitation , Faculty of Medicine AIN SHAMS University , for continuous guidance, valuable advice and generous thought in my work.

I would like to express my profound gratitude to PROF.HAYAM MOHAMED AREF, ASS. Professor of INTERNAL MEDICINE & NEPHROLOGY, Faculty of Medicine AIN SHAMS University, for her generous support and kind cooperation.

I would like to express my thanks to PROF RANIA HAMDY,Assistant Professor of Clinical Pathology ,Faculty of Medicine AIN SHAMS university, for help to complete this work.

I would like also to express my thanks to DR HAITHAM EZZAT ABD-EL AZIZ Lecturer Of Internal Medicine & Nephrology Faculty of Medicine AIN SHAMS University, for his support and sympathy during accomplishment of my work.

Finally all my love and thanks to my family for help and support.

CONTENTS

List of contents	Page
• LIST OF TABLES.....	I
• LIST OF FIGURES.....	IV
• LIST OF ABBREVIATIONS.....	VI
• INTRODUCTION.....	1
• AIM OF THE WORK	4
• REVIEW OF LITERATURE.....	5
• CHAPTER 1:SYSTEMIC LUPUS ERYTHEMATOSUS.....	5
• CHAPTER 2:LUPUS NEPHRITIS	32
• CHAPTER 3:NATURAL IMMUNOGLOBULIN M.....	83
• PATIENTS AND METHODS.....	93
• RESULTS.....	101
• DISCUSION.....	137
• SUMMARY AND CONCLUSION.....	158
• REFERENCES	165
• ARABIC SUMMARY	

LIST OF ABBREVIATIONS

Ab	: Monoclonal antibody.
ACE	: Angiotensin Converting Enzyme.
ACR	: American College of Rheumatology.
AGP	: α 1-acid-glycoprotein
ALMS	: the Aspreva Lupus Management Study
ANAs	: Anti-Nuclear Antibodies.
ANCA	: Antineutrophil cytoplasmic-antigen autoantibodies.
Anti-dsDNA	: Anti-Double stranded Deoxy Ribonucleic Acid.
<i>Anti La/SS-B</i>	: Extractable nuclear antigens
AP-1	: Activator protein-1.
APRIL	: A Proliferation-Inducing Ligand.
ARBs	: Angiotensin II Receptor Blockers.
ASCT	: Autologous stem cell transplantation.
AZA	: Azathioprine.
β2-GPI	: IgM antiphospholipid antibodies that bind to beta-2-glycoprotein I
B2 cells	: follicular B cells
BCR	: B cell receptors
BILAG	: British Isles Lupus Assessment Group.
BLyS	: B-lymphocyte Stimulator.
BUN	: Blood Urea Nitrogen.
BXSB	: In-bred strains of mice
BWF :	1 hybrid between NZ and WNZ
C1INH	: Complement 1 Inhibitor.
C1q	: Complement 1q.
C2	: Complement 2.
C3	: Complement 3.
C4	: Complement 4.
CAMs	: Cell adhesion molecules

cAMP	:Cyclic adenosine monophosphate.
CCR5	: C-C chemokine receptor type 5
cGN	:Crescent glomerulonephritis.
CH 50	: Total hemolytic complement.
CNS	:Central Nervous System.
CNV	: the gene copy number variation
CP	: ceruloplasmin
CRP	:Reactive Protein.
CTLA4	: Cytotoxic T-Lymphocyte Antigen 4
CXCR	:Human CXC chemokine receptors.
CXCL10	: chemokine (C-X-C motif) ligand 10
CYC	:Cyclophosphamide.
DARC	:Duffy antigen receptor for chemokines.
DCs	: Dendritic Cells
DLE	: Discoid lupus erythematosus.
DNA	: Double stranded DNA.
DN T cells	: Double negative T cells
DPLN	: diffuse proliferative lupus nephritis
DSG	: novel immunosuppressant 15-deoxyspergualin
EBV	:Epstein Barr Virus.
ECLAM	:European Consensus Lupus Activity Measurment.
ELNT	: The Euro-Lupus Nephritis Trial
ENA-78	:Epithelial neutrophil activating protein-78 .
ENAS	: Extractable nuclear antigen antibodies
ESR	:Erythrocyte Sedimentation Rate.
ESRD	:End stage renal disease.
EXPLORER	: Rituximab in patients with Severe Systemic Lupus Erythematosus
FAIM3	: Fas apoptotic inhibitory molecule 3
Fc	: Crystallizable fragment.
FcγR	: Fc gamma receptor

FhT cells	: Follicular helper T cells
GBM	: Glomerular basement membrane .
GC	:Glucocortecoid.
GM-CSF	: Granulocyte macrophage colony stimulating factor
GWAS	: Genome-wide association study
HA-IgG	: Heat-aggregated IgG
HLA	:Human Leukocyte Antigens.
HMGB1	: High mobility group box 1 protein
ICAM-1	: Intracellular adhesion molecule-1.
ICOS	: Inducing costimulator
IFN	:Interferon.
IgA	: Immunoglobulin A.
IgG	: Immunoglobulin G.
IgG2	: Immunoglobulin G subclass 2
IL	:Interleukin.
IP-10	: IFN-gamma-induced protein 10
ISN/RPS	:International Society of Pathology/Renal Pathology Society.
ITGAM	:Integrin- α -M
IVP	: Intravenous pyelogram.
$\kappa$$\beta$NF	: kappa beta nuclear factor
KIM-1	: kidney injury molecule-1
LAI	:Lupus Activity Index.
LDL	:Low density lipoproteins.
LN	:Lupus Nephritis.
LNDAI	: LN disease activity index
LUNAR	: The LUpus Nephritis Assessment with Rituximab
LPGDS	: lipocalin-type prostaglandin D-synthetase
mABs	: Monoclonal antibodies
MAC	: Complement membrane attack complex
MALDI-TOF MS	: Matrix Assisted Laser Desorption/Ionization Time Of Flight Mass Spectrometry

MASP	:Mannan-binding lectin-Associated Serine Protease.
MBL	:Mannan-Binding Lectin pathway.
MCP-1	:Monocyte chemoattractant proteins-1.
MCP-4	:Monocyte chemoattractant proteins-4.
MESNA	:Mercaptoethylamine sulfonate sodium.
MIP-1	:macrophage inflammatory proteins 1.
MLN	: membranous lupus nephritis
MMF	:Mycophenolate mofetil.
MPC-1	: Monocyte chemoattractant protein-1
MRL-Fas^{lpr}	: Mice homozygous for the apoptosis-defective Fas ^{lpr} mutation
mRNA	: Messenger ribonucleic acid.
NFAT	: Nuclear factor of activated T cells
NGAL	: Neutrophil Gelatinase-Associated Lipocalin
NIH	:National Institutes of Health.
NSAIDs	:Non Steroidal Anti-Inflammatory Drugs.
NZB	: New Zealand Black mice
NZWF1	: New ZealandWhite F1 mice
PCR	: Polymerase chain reaction.
(PD-1)	: Programmed death 1 costimulatory receptor
PDGF	: Platelet-derived growth factor
PTEC	: Proximal tubular epithelial cells
PTPN22	the protein tyrosine phosphatase Lyp
PTT	: Partial thromboplastin time.
RANTES	:Regulated upon activated normal T cell expressed and secreted
RTX	:Rituximab.
SB2M/SCysC	: Serum Beta 2-Microglobulin/ Cystatin C Index
SCLE	: Subacute cutaneous lupus erythematosus.
SHP-2	: Nonreceptor protein tyrosine phosphatase
SLAM	:Systemic Lupus Activity Measure.

SLE	:Systemic Lupus Erythematosus.
SLEDI	:Systemic Lupus Erythematosus Disease Activity Index.
SELDI-TOF MS	: Surface Enhanced Laser Desorption Ionization Time Of Flight Mass Spectrometry
SLICC	:Systemic Lupus International Collaborating Clinics.
SMIP	:Small Modular ImmunoPharmaceutical.
SNPs	: Single nucleotide polymorphisms
TCR	: T cell receptor
TdT	: terminal deoxynucleotidyl transferase
TF	: transferrin
TGF	: Transforming growth factor
TLR4	: Toll-like receptor 4
TNF-alpha	:Tumor Necrosis Factor alpha.
TRAIL	: TNF related apoptosis-inducing ligand
Tregs	: T regulatory cells
TWEAK	: TNF-related weak inducer of apoptosis
UV	: Ultraviolet.
Th2, th1	: Lymphocyte T helper 2, T helper1
Th17	: T helper 17
TLR	: Toll-like receptors
TOSO/FAIM3	: a distinct Fc receptor for IgM expressed on B cells
WHO	:World Health Organization classification.

--

List of Tables

Item	Page
Table A:	24
Table B: The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000.	25
Table C Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index.	29
Table (1): Comparison between the studied groups as regards general data	95
Table (2) Comparison between the studied groups as regards quantitative lab data by using one way ANOVA test	95
Table (3): Table (3) Comparison between the studied groups as regards qualitative lab data by using chi-square test.	95
Table (4) Comparison between the studied groups as regards SLEDI , SDI and MDRD using one way ANOVA test.	98
Table (5) Comparison between the studied groups as regards urinary IgM difference by using one way ANOVA test .	98
	98

Table6 . Frequency distribution of renal biopsy results among LN group:	
Table 7 . Comparison between different grades in renal biopsy regarding renal parameters in LN patients group :	99
Table 8 . Comparison between different grades in renal biopsy regarding disease activity scoring systems in LN group patients :	100
Table 9 . Comparison between different grades in renal biopsy regarding urinary IGM in LN group patients	100
Table (10) Correlation between urinary IgM versus different variables among control group	101
Table (11) Correlation between urinary IgM versus different variables among LN group by using Spearman correlation.	101
Table (12) Correlation between urinary IgM versus different variables among SLE group by using Spearman correlation.	102
Table (13) Correlation between urinary IgM versus	102

different variables among LN group by linear regression analysis	
Table (14) Correlation between nephropathy versus different predictors by binary logistic regression analysis	102
Table 15: Multi-Regression Analysis for predictors of LN activity in SLE group versus LN group:	103
Table 16 ROC curve analysis showing the diagnostic performance of u-IgM and creatinine, BUN and protienuria for discriminating patient with LN from those SLE without nephritis	104
Table 17 ROC curve analysis showing the diagnostic performance of GFR , SDI-global , pyuria and heamaturia for discriminating patients with LN from those SLE without nephritis.	108
Table 18 ROC curve analysis showing the diagnostic performance of u-IgM and SLEDAI and their combination for discriminating patient with LN from those SLE without nephritis	111
Table 19 ROC curve analysis showing the diagnostic	114

<p>performance of</p> <p>u-IgM and combination of Anti ds-DNA with u-IgM for discriminating patients with LN from SLE without nephritis</p>	
<p>Table 20 ROC curve analysis showing the diagnostic performance of</p> <p>u-IgM and combination of u-IgM with Anti ds-DNA and Proteinuria for discriminating those with SLE from healthy controls.</p>	121
<p>Table 21 ROC curve analysis showing the diagnostic performance of</p> <p>combination of u-IgM with Anti ds-DNA and Proteinuria for discriminating patients with SLE from healthy controls.</p>	125

List of Figures

Item	Page
Figure (1): ROC curve analysis showing the diagnostic performance of Proteinuria, BUN, creatinine and u-IgM for discriminating patients with LN from those SLE	105
Figure (2): ROC curve analysis showing the diagnostic performance of GFR , SDI-global , pyuria and heamaturia for discriminating patients with LN from those SLE	18
Figure (3): ROC curve analysis showing the diagnostic performance of u-IgM and SLEDAI and their combination for discriminating patients with LN from those SLE without nephritis.	111
Figure (4): ROC curve analysis showing the diagnostic performance of u-IgM and Anti ds-DNA and their combination for discriminating patients with LN from SLE	114
Figure (5): Comparison between SLE patients group and LN patients group regarding SLEDAI-2K (global: 0-105).	115
Figure (6) : Comparison between SLE patients group and LN patients group regarding renal domain SLEDAI-2K (0-16),	115
Figure (7): Comparison between SLE patients group and LN patients group regarding SDI global damage score(0-47)	116
Figure (8): Comparison between SLE patients group and LN	116